Navigation Links
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
Date:2/5/2009

n oral capsule dose. ------------------------------------------------------------------------- Secondary Endpoints Pharmacokinetics; definition of recommended dose for Phase II studies; preliminary evaluation of vascular- targeting activity. ------------------------------------------------------------------------- Blinding Status Not blinded. ------------------------------------------------------------------------- Product Development Status Drug substance and drug product are manufactured to GMP standards. ------------------------------------------------------------------------- Treatment Method Route Oral Frequency Two weekly cycle Dose-levels Dose-escalation study over 8 dose-levels (15 to 164 mg/m2) ------------------------------------------------------------------------- Number of Trial Subjects 21 ------------------------------------------------------------------------- Subject Selection Criteria Eligible patients must have a solid tumor that is metastatic or unresectable for which standard therapies do not exist or are no longer effective. ------------------------------------------------------------------------- Trial Locations Adelaide, Brisbane, and Townsville, Australia. ------------------------------------------------------------------------- Trial Standard ICHGCP -------------------------------------------------------------------------

About Cytopia


'/>"/>
SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytopia Scientific Presentations on JAK2 Inhibitor Program
2. Cytopia Commences Second Phase II Study in Brain Cancer
3. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
4. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
5. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
6. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
7. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
8. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
11. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  With the heroin epidemic in ... Jacksonville -based Lakeview Health drug and alcohol ... to explain why fentanyl is causing a new wave ... times more potent than pharmaceutical grade heroin and often ... risk of death skyrockets. "Fentanyl can be ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" report ... the trade name of Avastin, bevacizumab injection is the ... it was approved by CFDA to treat metastatic colorectal ... all come from Roche and its subsidiary ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2Investigation Report on China's Bevacizumab Market 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2
... Reportlinker.com announces that a new market research report ... Sepsis http://www.reportlinker.com/p0484945/Epidemiology-Sepsis.html ... seven major markets, especially in intensive care units. Datamonitor ... incident cases of severe sepsis in the seven major ...
... LAKE FOREST, Ill., April 26, 2011 Hospira, Inc. ... pharmaceutical and medication delivery company, today reported results for ... for the quarter were $1.0 billion, and adjusted* diluted ... specified items as described later in this press release ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Sepsis 2Hospira Reports First-Quarter 2011 Results 2Hospira Reports First-Quarter 2011 Results 3Hospira Reports First-Quarter 2011 Results 4Hospira Reports First-Quarter 2011 Results 5Hospira Reports First-Quarter 2011 Results 6Hospira Reports First-Quarter 2011 Results 7Hospira Reports First-Quarter 2011 Results 8Hospira Reports First-Quarter 2011 Results 9Hospira Reports First-Quarter 2011 Results 10Hospira Reports First-Quarter 2011 Results 11Hospira Reports First-Quarter 2011 Results 12Hospira Reports First-Quarter 2011 Results 13
(Date:8/29/2015)... , ... August 29, 2015 , ... Dr. Tim Novelli, ... His mission is to increase acceptance of the chiropractic field in the military. ... further debilitate them. Although Chiropractic was made available to the VA program over ...
(Date:8/29/2015)... AB (PRWEB) , ... August 29, 2015 , ... ... heart failure, angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at ... such as angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or ...
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
(Date:8/28/2015)... FL (PRWEB) , ... August 28, 2015 , ... The ... potential workers are qualified for the position they are applying for, they are unable ... this, many employers are considering altering drug testing policies in order to be able ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Devices:, Understanding the FDA’s Position and Best Practices for Compliance, **Presented by ... , This workshop, chaired by internationally renowned expert Fubin Wu, has been ...
Breaking Medicine News(10 mins):Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5
... In medical breakthrough research findings, researchers have been able ... which had significant brain degeneration. ,Researchers from University ... so that the mice have a clinical condition very ... researchers used transgene to check the loss of memory. ...
... form of the enzyme aldehyde dehydrogenase// (ALDH)that is responsible ... consuming alcohol. ,Researchers from Mitsukoshi Health and Welfare ... to hangovers in individuals who have a particular genetic ... important enzyme involved in the removal of acetaldehyde, which ...
... women with sexual difficulties was rejected by a panel of ... ,Procter & Gamble, global manufacturer of household products, ... menopausal after ovarian surgery however due to the rejection by ... hold until more data is available to assess the drug. ...
... a “black box warning” to three asthma drugs//, ... advised the manufacturers that the drug should carry ... breathing. ,Adavir and Serevent are manufactured ... manufacturers the drug Foradil which contains a different ...
... constantly coming up with new strategies// and technologies to ... ,Deputy director BK Karna of Indian Institute ... bring in novel features to prevent proliferation of duplicated ... closure and tamper evidence packaging they are yet to ...
... University of California-San Francisco has published that weight loss// ... by increasing heart beat rate and blood pressure. ... homeostasis. ,The study spearheaded by Dr. Christine A. ... experimental group of 16 healthy adults. Two tests were ...
Cached Medicine News:Health News:Testosterone patch for women Rejected For safety Reasons 2Health News:FDA gives “black box warning” against three asthma dru 2Health News:The Use of Radio Frequency Identification ( RFID) to tackle the growing menace of counterfeit drugs 2
... planning capabilities such as automatic image fusion ... arc settings or for frameless procedures. ... Improving the OR workflow . Flexible ... surgeon the flexibility to start the planning ...
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... This unique system uses prolene as thread-guide ... The hollow Ritleng Probe is inserted into the ... fed through it. The probe is then withdrawn ... mm 0.64 mm diam silicone tubing into place. ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
Medicine Products: